Physician profile
Alan D Baribeau
NPI 1952301384
$11,236.56
in general payments reported to CMS, 2019-2025
32 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,740 · 2020: $856 · 2021: $780 · 2022: $1,056 · 2023: $1,583 · 2024: $1,661 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,803.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,421.66 | 2019-2022 | |
| Abbvie INC. | $1,596.60 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $914.40 | 2019-2021 | |
| Biotissue Holdings INC. | $829.27 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $730.07 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $647.46 | 2019-2022 | |
| Alcon Vision LLC | $545.81 | 2022-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Novartis Pharmaceuticals Corporation | $490.47 | 2019-2022 | |
| Dompe US, INC. | $362.17 | 2021-2025 | Oxervate |
| Astellas Pharma US INC | $305.22 | 2024-2025 | Izervay |
| Amgen INC. | $275.82 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $225.04 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $203.09 | 2019-2021 | |
| Sight Sciences, INC. | $191.99 | 2020-2025 | Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $147.06 | 2025 | Acthar |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $132.88 | 2019 | |
| Sun Pharmaceutical Industries INC. | $132.67 | 2019-2023 | Cequa |
| Eyevance Pharmaceuticals LLC | $124.99 | 2021 | |
| Glaukos Corporation | $119.11 | 2019 | |
| Akorn, INC. | $109.19 | 2020 | |
| Horizon Therapeutics Plc | $108.39 | 2023 | Tepezza |
| Nova Eye, INC. | $105.13 | 2025 | |
| Thea Pharma INC. | $103.05 | 2022-2025 | Iyuzeh |
| Optos, INC. | $99.36 | 2019 | |
| Tearlab Corp | $99.11 | 2023 | Tearlab Osmolarity System |
| Carl Zeiss Meditec, INC. | $58.44 | 2021 | |
| Akorn Operating Company LLC | $39.87 | 2021 | |
| Kala Pharmaceuticals, INC. | $29.92 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $25.67 | 2024 | Xdemvy |
| Shire North American Group INC | $23.89 | 2019 | |
| Genentech USA, INC. | $22.05 | 2023 | Xofluza |
| Ivantis, INC | $16.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Baribeau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.